Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
March 02, 2022 14:15 ET
|
Athira Pharma, Inc.
Active metabolite of fosgonimeton (ATH-1017) enhances the HGF/MET system, resulting in neurotrophic and procognitive effects In two unique disease models, ATH-1020 reduces depression-like...
Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
February 22, 2022 07:05 ET
|
Athira Pharma, Inc.
Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models First presentation of preclinical data from ATH-1020 candidate for...
Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
February 22, 2022 07:00 ET
|
Athira Pharma, Inc.
Fosgonimeton demonstrated a statistically significant improvement of Event-Related Potential (ERP) P300 latency as compared with placebo in Alzheimer’s disease patients Fosgonimeton was...
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
January 31, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
January 25, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Provides 2022 Pipeline Outlook
January 05, 2022 07:00 ET
|
Athira Pharma, Inc.
Topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22 LIFT-AD Phase 3 Alzheimer’s disease study sample size increased to strengthen statistical power of co-key secondary endpoints and...
Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update
November 10, 2021 16:05 ET
|
Athira Pharma, Inc.
– Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 – – Presented program updates...
Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
November 10, 2021 11:50 ET
|
Athira Pharma, Inc.
– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira...
Athira Pharma to Present at Upcoming Investor Conferences
November 08, 2021 07:00 ET
|
Athira Pharma, Inc.
-Stifel 2021 Virtual Healthcare Conference-- Jefferies 2021 London Healthcare Conference- BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage...
Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300
October 29, 2021 07:00 ET
|
Athira Pharma, Inc.
Neurologist Dr. John Michael Olichney to discuss utility of P300 to assess cognitive function Webinar to be held Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET BOTHELL, Wash., Oct. 29, 2021 (GLOBE...